SCHEMBL17419486

SCHEMBL17419486

C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@H]43)[C@@H]1CC[C@@H]2OC(=O)CCC1CCCC1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 5/20 0.74
▸ MAPT P10636 4/20 0.74
▸ CYP3A4 P08684 4/20 0.58
▸ PGR P06401 3/20 0.58
▸ AR P10275 2/20 0.58
▸ CYP2C19 P33261 2/20 0.58
▸ ESR1 P03372 1/20 0.58
▸ ADORA3 P0DMS8 1/20 0.58
▸ PTGS1 P23219 1/20 0.58
▸ PDE4A P27815 1/20 0.58
▸ PDE3A Q14432 1/20 0.58
▸ MEN1 O00255 1/20 0.58
▸ TP53 P04637 1/20 0.58
▸ MAPK1 P28482 1/20 0.58
▸ KMT2A Q03164 1/20 0.58
▸ SERPINA6 P08185 2/20 0.58
▸ ALDH1A1 P00352 2/20 0.58
▸ SLC22A1 O15245 1/20 0.58
▸ SHBG P04278 1/20 0.58
▸ THRB P10828 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL604525 0.99 LMNA (0.73) LMNAMAPTCYP3A4PGRAR
SCHEMBL21067996 0.91 MAPT (0.84) LMNAMAPTCYP3A4PGRAR
SCHEMBL23752494 0.88 MAPT (0.78) LMNAMAPTCYP3A4PGRAR
SCHEMBL17419472 0.88 MAPT (0.78) LMNAMAPTCYP3A4PGRAR
SCHEMBL11854733 0.87 LMNA (0.59) LMNAMAPTCYP3A4PGRAR
Cyclohexane SCHEMBL8027519 0.87 MAPT (0.76) LMNAMAPTCYP3A4PGRAR
SCHEMBL343128 0.86 MAPT (0.79) LMNAMAPTCYP3A4PGRAR
SCHEMBL17419490 0.86 MAPT (0.98) LMNAMAPTCYP3A4PGRAR
SCHEMBL11121455 0.85 MAPT (0.75) LMNAMAPTCYP3A4PGRAR
SCHEMBL5155074 0.85 LMNA (0.55) LMNAMAPTCYP3A4PGRAR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250281509-A1 SEQUENTIAL HORMONE THERAPY TO IMPROVE SURVIVAL AND ENHANCE RESPONSE TO IMMUNE THERAPY IN MEN WITH PROSTATE CANCER THE JOHNS HOPKINS UNIVERSTY 2025-09-11 — — US disclosed
US-20160008376-A1 Compositions, Methods and Uses for Treating Gender-Biased Immune Disorders BIOCOPEA LIMITED (GB) 2016-01-14 — — US disclosed
WO-2016005599-A1 COMPOSITIONS, METHODS AND USES FOR TREATING GENDER-BIASED IMMUNE DISORDERS BIOCOPEA LIMITED (GB) 2016-01-14 — — WO disclosed
Send feedback